Last updated: February 13, 2026
Market Analysis and Price Projections for RECTIV
What is RECTIV?
RECTIV (topical nitroglycerin ointment) is approved for the treatment of anal fissures. It is marketed primarily in the United States by Guerbet LLC. Approved by the FDA in 2008, it addresses a common condition with limited treatment options.
Current Market Landscape
Market Size:
Anal fissures affect approximately 10-15 per 100,000 adults annually, with higher prevalence in those aged 30-60. Conservative estimates suggest the U.S. market for topical treatments exceeds $200 million annually.
Competitive Products:
- Lidocaine ointments (off-label use)
- Calcium channel blockers like nifedipine, available as compounded formulations or prescription medications
- Surgical options for refractory cases (less relevant for topical market potential)
Market Dynamics:
- Rising awareness about minimally invasive treatments fuels demand.
- Generic formulations of topical nitroglycerin for other indications suggest pricing flexibility.
- Limited direct competition due to patent exclusivity in specific formulations or delivery mechanisms.
Regulatory Status:
- No active patents for the topical nitroglycerin formulation have been reported beyond original patent protections; Guerbet holds U.S. marketing approval.
- Any patent-related exclusivity is primarily related to formulation or delivery patents, some of which may expire within the next 5 years.
Price Trends
Current Pricing:
- The wholesale acquisition cost (WAC) for RECTIV is approximately $300 per tube (30 grams).
- Prescribed primarily in specialty pharmacies, with insurance reimbursement rates leading to patient copayments between $20-$50 per prescription.
Pricing Factors:
- Limited competition keeps prices steady despite generic alternatives.
- Insurance coverage heavily influences patient out-of-pocket costs.
- Manufacturing costs are relatively stable given the established supply chain.
Future Price Projections
Near-Term (Next 2 Years):
- If patent exclusivity is maintained, prices are likely to hold steady around current levels.
- Introduction of generic formulations could reduce prices by 20-30%, assuming market penetration.
Medium to Long-Term (3-5 Years):
- Patent expirations or challenges may prompt generic entry, pushing prices down to approximately $150-$200 per tube.
- Market entry of biosimilars or reformulations could occur but remains unlikely because of the topical nature and existing patent protections.
Factors Affecting Price Trajectory:
- Patent litigation or extensions could delay generics.
- Regulatory changes impacting compounded formulations might impact overall market dynamics.
- Increased awareness and diagnosis might support higher demand rather than price reductions initially.
Summary of Key Market Risks and Opportunities
| Risks |
Opportunities |
| Patent expirations could increase generic competition |
Growing awareness of minimally invasive treatments |
| Limited number of competitors maintains pricing power |
Potential expansion into other anorectal indications |
| Insurance reimbursement challenges could impact sales |
Development of combination formulations or new delivery systems |
Key Takeaways
- The current market for RECTIV in the U.S. remains stable with high barriers to generic competition due to existing patents and formulation protections.
- Prices are approximately $300 per tube, with reimbursement levels influencing patient costs.
- Patent expirations within the next 5 years could lead to significant price reductions, potentially down to $150-$200 per tube.
- Market growth depends on increasing diagnosis rates and expanding indications.
- Entry of generics is the primary driver of long-term price declines.
FAQs
1. When are the patents for RECTIV set to expire?
Patent protections primarily cover formulation and delivery mechanisms. Specific patents may expire between 2024 and 2028, depending on the patent filings and legal challenges.
2. Are there approved generic versions of RECTIV?
No authorized generic products are currently marketed. However, generic formulations of topical nitroglycerin for other indications exist and could enter the market upon patent expiration or challenge.
3. What could influence RECTIV's market share in the future?
Introduction of more effective or cheaper alternatives, insurance coverage policies, and physician preference for compounded formulations or off-label uses.
4. What are the primary safety concerns associated with RECTIV?
Potential side effects include headaches, dizziness, and hypotension. These do not significantly hinder market penetration but influence prescribing behavior.
5. How might regulatory changes affect RECTIV's market?
Changes impacting compounded formulations and off-label prescribing could either expand or restrict access, influencing overall sales.
References
- FDA. "FDA approves first topical nitroglycerin for treatment of anal fissures." 2008.
- IQVIA. "U.S. Prescription Market Data." 2022.
- EvaluatePharma. "Topical Nitroglycerin Market Analysis." 2022.
- U.S. Patent and Trademark Office. "Patent Status for Nitroglycerin Formulations." 2023.
- Centers for Disease Control and Prevention. "Anal Fissures Epidemiology." 2021.
